Drug profile · INN
mipomersen sodium
KYNAMRO
mipomersen sodium (KYNAMRO) is a apo-b 100 mrna antisense inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — mipomersen sodium
- US status
- approved
- Class
- Cardiovascular system (C10)
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 8
- Data quality
- 0.84
Quick answer
mipomersen sodium (KYNAMRO) is a apo-b 100 mrna antisense inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Apo-B 100 mRNA antisense inhibitor
Primary target: Apo-B 100 mRNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | refused | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is mipomersen sodium?
mipomersen sodium (KYNAMRO) is a apo-b 100 mrna antisense inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for mipomersen sodium?
KYNAMRO is a marketed brand name for mipomersen sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mipomersen sodium?
mipomersen sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.